Detalhe da pesquisa
1.
Preclinical Evaluation of Invariant Natural Killer T Cells Modified with CD38 or BCMA Chimeric Antigen Receptors for Multiple Myeloma.
Int J Mol Sci
; 22(3)2021 Jan 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-33499253
2.
Improving CLL Vγ9Vδ2-T-cell fitness for cellular therapy by ex vivo activation and ibrutinib.
Blood
; 132(21): 2260-2272, 2018 11 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-30213872
3.
Generation and characterization of CD1d-specific single-domain antibodies with distinct functional features.
Immunology
; 149(1): 111-21, 2016 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-27312006
4.
Enhanced CD1d phosphatidylserine presentation using a single-domain antibody promotes immunomodulatory CD1d-TIM-3 interactions.
J Immunother Cancer
; 11(12)2023 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38040419
5.
A bispecific T cell engager recruits both type 1 NKT and Vγ9Vδ2-T cells for the treatment of CD1d-expressing hematological malignancies.
Cell Rep Med
; 4(3): 100961, 2023 03 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-36868236
6.
Enhancement of NK Cell Antitumor Effector Functions Using a Bispecific Single Domain Antibody Targeting CD16 and the Epidermal Growth Factor Receptor.
Cancers (Basel)
; 13(21)2021 Oct 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-34771609
7.
A Bispecific Single-Domain Antibody Boosts Autologous Vγ9Vδ2-T Cell Responses Toward CD1d in Chronic Lymphocytic Leukemia.
Clin Cancer Res
; 27(6): 1744-1755, 2021 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33451981
8.
A Bispecific Antibody Antagonizes Prosurvival CD40 Signaling and Promotes Vγ9Vδ2 T cell-Mediated Antitumor Responses in Human B-cell Malignancies.
Cancer Immunol Res
; 9(1): 50-61, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33177109
9.
A single-domain bispecific antibody targeting CD1d and the NKT T-cell receptor induces a potent antitumor response.
Nat Cancer
; 1(11): 1054-1065, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35122066
10.
Corrigendum: CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: α-Galactosylceramide and Beyond.
Front Immunol
; 9: 2606, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30519237
11.
CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: α-Galactosylceramide and Beyond.
Front Immunol
; 9: 1519, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30013569
12.
A bispecific nanobody approach to leverage the potent and widely applicable tumor cytolytic capacity of Vγ9Vδ2-T cells.
Oncoimmunology
; 7(1): e1375641, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-29296532
13.
A visceral pseudoaneurysm: management by EUS-guided thrombin injection.
Gastrointest Endosc
; 73(2): 392-5, 2011 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-20630509
14.
Exploiting the CD1d-iNKT cell axis for potentiation of DC-based cancer vaccines.
Methods Mol Biol
; 1139: 155-65, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-24619678
15.
Bispecific antibody platforms for cancer immunotherapy.
Crit Rev Oncol Hematol
; 92(3): 153-65, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25195094
16.
Polymerase chain reaction amplifying mycobacterial DNA from aspirates obtained by endoscopic ultrasound allows accurate diagnosis of mycobacterial disease in HIV-positive patients with abdominal lymphadenopathy.
Ultrasound Med Biol
; 40(9): 2031-8, 2014 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-25023118